QUANTUM MRI STARTUP NVISION RAISES $55M SERIES B

NVision, which develops quantum-enhanced MRI imaging technology, announced the Series B funding on Wednesday with Abbott as lead investor. The round values the startup in the $250M-$300M range. The company specializes in quantum imaging solutions designed to improve magnetic resonance imaging capabilities. Quantum technology offers potential advantages in sensitivity and image quality compared to conventional MRI systems, a factor likely attractive to Abbott, a major healthcare equipment manufacturer. Abbott's involvement signals confidence in NVision's technology and commercial viability. The healthcare giant's participation could accelerate the startup's path to market and provide distribution channels for its quantum imaging systems. NVision's roadmap includes an aggressive funding trajectory. Beyond the current Series B, the startup is targeting a Series C raise of $100M or more in the latter half of 2026. This aggressive capital strategy suggests the company plans rapid scaling of operations, manufacturing capacity, or market expansion. Quantum imaging represents an emerging frontier in medical technology. While still relatively early-stage, companies pursuing quantum-enhanced medical devices have attracted significant venture and corporate investment. NVision's funding rounds reflect growing industry interest in commercializing quantum applications in healthcare. The startup's German base positions it within Europe's growing quantum technology ecosystem, which has received substantial government support and investment backing. With $55M secured and a clear path to substantial additional capital planned for 2026, NVision appears well-positioned to advance its quantum MRI technology toward clinical deployment and commercialization in the medical imaging market.